newsfilter
← Latest News
GlobeNewswire·

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug